A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MK-1026-011 (BELLWAVE-011)
NCT06136559
 Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Chronic Lymphocytic Leukemia |
Dr. Samuel Nadeau
Marie-Eve Fournier
418-724-3000 poste 8029
|
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
PACIFIC-9
NCT05221840
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Non Small Cells - Lung |
Dr. Arnaud Blanchet-St-Pierre
Isabelle Gagnon
418-724-3000 poste 8029
|
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ? 50%) and Without Actionable Genomic Alterations
TROPION-Lung10
NCT06357533
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Non Small Cells - Lung |
Dr. Katerine Marquis
Isabelle Gagnon
418-724-3000 poste 8029
|
Groupe d'étude en oncologie du Québec